Offering stock – Originals CIPO Wed, 10 Aug 2022 20:04:37 +0000 en-US hourly 1 Offering stock – Originals CIPO 32 32 Cerevel Therapeutics Announces Proposed Public Offering of Common Shares Wed, 10 Aug 2022 20:01:29 +0000

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — Cerevel Therapeutics Holdings, Inc. (“Cerevel,” “we,” “us,” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries brain to treat neuroscience diseases, today announced the launch of a public offering of $250.0 million of common stock. Under the offering, Cerevel plans to grant underwriters a 30-day option to purchase up to an additional $37.5 million of common stock at the public offering price, less underwriting discounts and fees. . The offering of Common Shares is subject to market and other conditions and there can be no assurance as to whether the offering will be successful or as to the actual size or terms of the offer. offer. All shares for sale under the proposed common stock offering will be sold by Cerevel.

Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Jefferies LLC and Evercore Group LLC are acting as joint bookrunners for the offering. Loop Capital Markets LLC and Siebert Williams Shank & Co., LLC act as co-managers.

In conjunction with the common stock offering, Cerevel is offering to qualified institutional purchasers, under an offer exempt from registration under the Securities Act of 1933, as amended, an aggregate principal amount of $250.0 million of senior convertible bonds due 2027 (the “Bonds”). As part of the note offering, Cerevel plans to grant initial purchasers of the notes a 13-day option to purchase up to an additional aggregate principal amount of $37.5 million of the notes. The Common Share Offering is not conditional upon the completion of the Concurrent Note Offering, and the Concurrent Note Offering is not conditional upon the completion of the Common Share Offering.

Cerevel intends to use the net proceeds from the common stock offering and, if completed, the concurrent note offering: (i) to support the continued development of emraclidine, including to accelerate activities permitting registration; (ii) assess the potential of emraclidine in other populations, including Alzheimer’s disease psychosis; (iii) accelerate market development and pre-commercial planning activities for emraclidine and tavapadon; (iv) to advance the remaining programs in its pipeline, including arigabat, and its other promising early-stage programs, including CVL-354, its selective KORA; and (v) for working capital and other general business purposes, including to expand its cash trail.

A registration statement relating to the common stock offering was filed with the Securities and Exchange Commission (“SEC”) on November 10, 2021 and is effective. The offering of Common Shares will be made only by means of a prospectus supplement and the accompanying prospectus. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained, when available, from the SEC’s website at or by contacting the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New NY 10014, by e-mail at [email protected]; offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by phone at 1-866-471-2526 or by email at [email protected]; offices of Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by e-mail at [email protected]; or the offices of Evercore Group LLC, 55 East 52nd Street, 35th Floor, New York, NY 10055, by phone at (888) 474-0200 or by email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, and there will be no offer or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or territory.

About Cerevel Therapeutics

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company tackles disease with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diverse pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscientific diseases, including Parkinson’s disease, epilepsy, schizophrenia and dementia-related apathy . Based in Cambridge, Mass., Cerevel Therapeutics advances its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Special note regarding forward-looking statements

This press release contains forward-looking statements based on management’s beliefs and assumptions and on information currently available to management. In some instances, you can identify forward-looking statements by the following words: “may”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “anticipate”. “, “believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “in progress” or the negative form of these terms or any other comparable terminology, although not all forward-looking statements not contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from the information expressed or implied by these forward-looking statements. Although we believe we have a reasonable basis for each forward-looking statement contained in this press release, we caution that such statements are based on a combination of facts and factors currently known to us and our projections for the future, about of which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, express or implied statements regarding the terms of the proposed public offering of common stock, including our expectations regarding the grant to the underwriters of the offer of a 30-day option to purchase additional shares, the terms of the concurrent offering of the Notes, including our expectation that the initial purchasers of this offering will be granted a 13-day option to purchase Notes additional information, our intentions with respect to the use of proceeds and the completion, timing and size of the proposed public offering of common shares and the concurrent offering of notes. We cannot assure you that the forward-looking statements contained in this press release will prove to be accurate. Also, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or implied in the forward-looking statements due to a variety of risks and uncertainties, including: clinical trial results may not be favorable; uncertainties inherent in the product development process (including regarding the timing of results and whether those results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or our ability to raise additional capital; whether and when, if any, our product candidates will receive approval from the FDA or other regulatory authorities, and for what indications, if any; competition from other biotechnology companies; uncertainties regarding the protection of intellectual property; and other risks identified in our filings with the SEC, including those listed under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, our quarterly reports on Form 10-Q for the quarters ended March 31 and June 30, 2022 and our subsequent filings with the SEC. In light of the material uncertainties in these forward-looking statements, you should not consider these statements to be a representation or warranty by us or anyone else that we will achieve our goals and plans within a specified time frame, or at all. The forward-looking statements contained in this press release represent our opinions as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may choose to update these forward-looking statements at some time in the future, we currently have no intention of doing so except as required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Anna RobinsonCerevel Therapeutics[email protected]

Investor contacts:Matthew CalistriCerevel Therapeutics[email protected]

main logo

Source: Therapeutic Cerevel

Roblox Stock Is Down As Net Loss Exceeds Expectations Tue, 09 Aug 2022 22:26:00 +0000

Text size

Alghanim operates in sectors such as building materials, retail, automotive and financial services.

It holds the franchise rights for Chevrolet and Cadillac, Honda and Lotus, Ford and Lincoln, among other car brands. The company also holds franchise rights to Costa Coffee in Kuwait and Wendy’s in the Middle East.

Gulf issuers raised more than $11 billion from IPOs in the first half of this year, according to Refinitiv data, outpacing European IPOs even as global markets remain volatile in the wake of the Russian invasion of Ukraine.

Join now for FREE unlimited access to

Reporting by Ahmed Hagagy; Editing by Susan Fenton

Our standards: The Thomson Reuters Trust Principles.

Streaming War Heats Up With Launch of NFL+; Which action will win? Sat, 06 Aug 2022 14:30:00 +0000

AAs the streaming industry grows with new companies entering the market, platforms are striving to stand out. Several streaming giants have tried to acquire the rights to different live sports broadcasts as they try to attract fans to their platforms.

Now, the launch of NFL+ has shaken up the industry again and may sideline live sports as a growth tactic for streamers.

A lost asset

The National Football League launched its own streaming service, NFL+, on July 25, giving subscribers access to hundreds of games a year for $4.99 a month, exclusively on mobiles and tablets. The service comes as several streaming companies vie for the rights to add live sports to their platforms.

Just this year Apple (NASDAQ:AAPL) obtained the broadcasting rights Friday night baseball and all Major League Soccer games on Apple TV+. Amazonit is (NASDAQ: AMZN) Prime Video now houses Thursday night football in a deal worth $11 billion. disney (NYSE: DIS) is also in the fight with its sports streamer ESPN+, which offers subscribers a variety of live sports like UFC matches, golf content, tennis, and more.

Some the biggest names in streaming have focused on live sports in hopes of attracting subscribers, but their efforts could be wasted if more sports leagues launch their own platforms at competitive prices.

At around $5 a month, NFL+ made it easy for football fans to add another streaming platform, and it also created competition for any companies that get the rights to stream NFL games through a TV. . For example, Amazon may have Thursday night footballbut consumers might still be inclined to subscribe to NFL+ to make sure they don’t miss any other games. And if America’s biggest sports league decided to stream its content independently, it could push other leagues to follow suit, leaving fewer sports available for the streaming giants to add to their content catalogs.

Consumer friendly

The majority of fans tend to favor a few select sports over many, which makes league-specific platforms optimal for consumers. Rather than paying for an expensive cable package or even a service like ESPN+ with access to dozens of sports subscribers don’t necessarily watch, consumers can save money by only paying for the content they want. .

Alongside NFL+, Formula 1, the increasingly popular motorsports series, has launched the F1 TV streaming service, offering subscriptions for as low as $2.99 ​​per month. If other leagues stuck to prices similar to NFL+ and F1 TV, consumers could choose specific leagues to subscribe to, potentially gaining access to two or more platforms for one competitive price.

Additionally, while ESPN+ will increase the cost of its subscriptions by 43%, from $6.99 per month to $9.99 in August, due to added content and licensing agreements, it League-specific streaming services are unlikely to experience many price increases. Services like NFL+ don’t have to worry about expensive content creation or licensing deals because their subscribers are more interested in watching live games, which belong to the leagues. Without the price increases and content losses suffered by some streaming services, subscriber retention and satisfaction for NFL+ should be higher.

The only caveat to NFL+ is that its content can only be viewed on mobile devices and tablets, though that’s not the case with F1 TV. While this may be a deal breaker for many NFL fans, giving the competition a leg up, consumers are increasingly spending more time on portable devices rather than watching TV. In 2014, media researchers Frank N. Magid Associates found that 60% of Americans between the ages of 8 and 64 preferred watching TV on a computer or smartphone. Then, in 2019, eMarketer found that the average American adult spends more time on a phone or tablet every day than watching TV.

As mobile streaming technology has grown since the studies were conducted, chances are that consumers will continue to choose portable devices over TVs. Either way, the content and competitive price of NFL+ still has the ability to steal subscribers from any company eyeing the TV rights to NFL games. Time will tell if the NFL’s strategy of targeting mobile and tablet users will pay off.

A new focus

While NFL+ and F1 TV have started a trend towards low-cost, league-specific streaming services, companies such as Amazon, Apple and Disney will need an alternative plan to gain subscribers. Fortunately, despite the removal of a potentially lucrative avenue for growth, the rise of sports-specific streamers does not pose a significant threat to most services. League-specific rigs can be low-cost, making them easily stackable with other subscriptions.

Streaming investors will want to note the success of NFL+ as it developed to better understand how its launch affects the market and whether it inspires other leagues to offer similar services.

10 stocks we like better than Amazon
When our award-winning team of analysts have stock advice, it can pay to listen. After all, the newsletter they’ve been putting out for over a decade, Motley Fool Equity Advisortripled the market.*

They have just revealed what they believe to be the ten best stocks for investors to buy now…and Amazon wasn’t one of them! That’s right – they think these 10 stocks are even better buys.

View all 10 stocks

* Portfolio Advisor Returns as of July 27, 2022

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a board member of The Motley Fool. Dany Cook has no position in the stocks mentioned. The Motley Fool holds positions and recommends Amazon, Apple and Walt Disney. The Motley Fool recommends the following options: January 2024 Long Calls at $145 on Walt Disney, March 2023 Long Calls at $120 on Apple, January 2024 Short Calls at $155 on Walt Disney and March 2023 Short Calls at 130 $ on Apple. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

NuZee announces proposed public offering of common shares Sat, 06 Aug 2022 00:30:00 +0000

PLANO, TX, August 5, 2022 /PRNewswire/ — NuZee, Inc. (NASDAQ: NUZE), a leading U.S. producer and co-packer of single-serve coffee formats, today announced that it has launched a public undertaking firm on its ordinary shares. NuZee intends to grant the underwriters a 45-day option to purchase up to an additional fifteen percent of the number of shares of its common stock offered under the public offering to cover over-allotments, if any. applicable. The public offering is subject to market conditions, and there can be no assurance as to whether or when the public offering may be completed, or as to the actual size or terms of the public offering.

NuZee intends to use the net proceeds of the offering for working capital and general corporate purposes and to acquire complementary businesses, acquire or license complementary products or technologies its own, although NuZee currently has no plans, commitments or agreements regarding any such use of the product for acquisitions or licenses as of the date of this press release.

Maxim Group LLC is acting as sole bookrunner for the public offering.

The public offering is being made pursuant to an effective shelf registration statement on Form S-3 which was filed with the United States Securities and Exchange Commission (SEC) on September 1, 2020 and declared effective on October 2, 2020. The securities will only be offered by way of a preliminary prospectus supplement and accompanying prospectus forming part of the effective registration statement. A preliminary prospectus supplement describing the terms of the public offering will be filed with the SEC and will be available on the SEC’s website at Copies of the preliminary prospectus supplement and accompanying prospectus relating to the public offering may be obtained, when available, by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, or by phone at (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. prior to registration or qualification. under the securities laws of such state or territory.

Forward-looking statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. NuZee cautions you that these statements are only predictions and that actual events or results may differ materially. These statements reflect NuZee’s current expectations, and NuZee does not undertake to update or revise these forward-looking statements, even if experience or future changes clearly indicate that the projected results expressed or implied in this statement or in other NuZee statements will not come true. In addition, such statements involve risks and uncertainties, many of which are beyond NuZee’s control, which could cause actual results to differ materially from the forward-looking statements. Statements relating to, among other things, the completion of the Common Share Offering and potential changes in market conditions are forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: NuZee’s plan to obtain financing for its operations, including the financing necessary to develop, manufacture and market its products; the impact on NuZee’s business from COVID 19, including supply chain disruptions; general market acceptance and demand for NuZee’s products; NuZee’s reliance on third-party roasters to roast and blend the coffee beans needed to manufacture its products and provide its co-packing services; NuZee’s ability to successfully achieve anticipated results of strategic transactions; the fact that certain of NuZee’s single-serve coffee products would have to be manufactured, processed and packaged for NuZee by its new partner on a purchase order basis pursuant to the parties’ agreement; the fact that sales are concluded on the basis of a purchase order without any written agreement between NuZee and its customers; and NuZee’s sales, marketing and manufacturing capabilities and strategy. For a description of additional factors that may cause NuZee’s actual results, performance or expectations to differ from any forward-looking statements, please see the information set forth in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of NuZee’s public filings and other filings by NuZee with the SEC.

About NuZee

NuZee, Inc., (NASDAQ: NUZE), is a leading co-packaging company for single-serve coffee formats that partners with companies to help them grow in the single-serve coffee category and house brand.

SOURCE NuZee, Inc.

Exelon Announces Price of Public Offering of Common Shares Fri, 05 Aug 2022 12:00:00 +0000

CHICAGO–(BUSINESS WIRE)–Exelon (Nasdaq: EXC) today announced the price for an underwritten public offering of 11,300,000 common shares for expected gross proceeds of approximately $500 million before deducting estimated offering costs. Under the offering, the underwriters have been granted a 30-day option to purchase up to an additional 1,695,000 common shares. The offering is expected to close on August 9, 2022, subject to satisfaction of customary closing conditions. The net proceeds of the offering will be used to permanently repay a portion of the borrowings under a $1.15 billion term credit facility.

Barclays Capital Inc., Goldman Sachs & Co. LLC, JP Morgan Securities LLC and Morgan Stanley & Co. LLC acted as joint bookrunners and underwriters for the offering.

A registration statement relating to the common stock offering has been filed with the United States Securities and Exchange Commission (SEC) effective August 3, 2022. The common stock offering is being made only by means of a prospectus supplement. and the accompanying prospectus. Before investing in these securities, potential investors should read the Prospectus Supplement and accompanying Prospectus for more complete information about Exelon and the Offering. Prospective investors may obtain these documents from the SEC at the SEC’s website at Alternatively, prospective investors may obtain copies of the prospectus supplement and accompanying prospectus relating to the offering by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, barclaysprospectus, (888) 603-5847; Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282 Attention: Prospectus Department, by phone: (866) 471-2526 or by email at com; JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Toll Free: 1-866-803-9204; and Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any common stock of Exelon and will not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be illegal. .

Cautions Regarding Forward-Looking Information

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. Words such as “could”, “may”, “expect”, “anticipate”, “will”, “target”, “goals”, “project”, “intend”, “plan” , “believes”, “seeks”, “estimates”, “forecasts” and variations of these words, and similar expressions which reflect our current opinions with regard to future events and operational, economic and financial performance, are intended to identify these forward-looking statements.

Factors that could cause actual results to differ materially from the forward-looking statements made by Exelon include the factors discussed here, as well as those discussed in (1) Exelon’s 2021 Annual Report on Form 10-K filed with the SEC on February 25, 2022 in Part I, ITEM 1A. Risk factors; (2) Exelon’s Current Report on Form 8-K filed with the SEC on June 30, 2022 to restate Exelon’s consolidated financial statements and certain other financial information originally included in the 2021 Form 10-K in (a) Part II, ARTICLE 7. Management report and analysis of the financial situation and operating results and (b) Part II, ITEM 8. Financial statements and additional data: Note 17, Commitments and contingencies; (3) Exelon Second Quarter 2022 Quarterly Report on Form 10-Q (filed with the SEC on August 3, 2022) in (a) Part II, ITEM 1A. Risk Factors, (b) Part I, ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations, and (c) Part I, ITEM 1. Financial Statements: Note 12, Commitments and Contingencies; and (4) other factors discussed in Exelon’s filings with the SEC.

Investors are cautioned not to place undue reliance on any such forward-looking statements, written or oral, which speak only as of the date of this press release. Exelon undertakes no obligation to release any revisions to its forward-looking statements to reflect events or circumstances after the date of this press release.

About Exelon

Exelon (Nasdaq: EXC) is a Fortune 200 company and the nation’s largest utility company, serving more than 10 million customers through six fully regulated transmission and distribution utilities – Atlantic City Electric (ACE) , Baltimore Gas and Electric (BGE), Commonwealth Edison (ComEd), Delmarva Power & Light (DPL), PECO Energy Company (PECO) and Potomac Electric Power Company (Pepco). More than 18,000 Exelon employees dedicate their time and expertise to supporting our communities through reliable, affordable and efficient energy delivery, workforce development, equity, economic development and to volunteering. Follow Exelon on Twitter @Exelon.

PSE accepts SPNEC share offer Thu, 04 Aug 2022 17:47:02 +0000

The Philippine Stock Exchange (PSE) has given its approval to the stock rights offering (SRO) of solar power plant company Solar Philippines Nueva Ecija Corp. (SPNEC) to list approximately 1.88 billion shares (1,875,649,995).

In its notice of approval dated July 28, 2022, the PSE also approved the proposed schedule of the SROs, with an ex-date of August 22, 2022, a record date of August 25, 2022 and an offer period at from August 30, 2022. to September 5, 2022.

Last month, the Securities and Exchange Commission also issued an exempt transaction confirmation confirming that the solar company’s planned SRO is exempt from the registration requirements of the Securities Regulation Code.

SPNEC plans to offer the shares in a price range of 1.50 to 1.76 pesos per share, according to its July 11, 2022 prospectus.

The company is looking to raise around 2.8 billion pesos to 3.3 billion pesos from the supply which will then be allocated to project development (including securing land and off-take agreements).

Get the latest news

delivered to your inbox

Sign up for the Manila Times daily newsletters

By registering with an email address, I acknowledge that I have read and accept the terms of use and the privacy policy.

It also supports SPNEC’s goal of developing 10 gigawatts of solar projects by 2025, made possible by its increase in authorized share capital and asset-for-equity exchange with its parent company, Solar Philippines.

The company’s developments include the Terra Solar 3.5 GW 4.5 gigawatt-hour solar battery project, which plans to supply Meralco with 850 megawatts (MW) of average merit. This was billed as the “largest solar project in the world” and would be more than twice the total solar operating capacity in the Philippines today.

These are also projects that were contracted through the Department of Energy’s green power auction, in which Solar Philippines won 70% of all renewable energy capacity in the auction ( 1,380 MW out of 1,967 MW) and 91% of all solar capacity (1,350 MW out of 1,490 MW).

Solar Philippines’ shares in these projects are part of the assets that would be held by SPNEC after the share exchange.